BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...it will start a global Phase II trial this half of bavituximab, its mAb against phosphatidylserine...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

...proof-of-concept trials, starting with bavituximab in gastric cancer next quarter. Oncologie acquired the mAb against phosphatidylserine...
BioCentury | Jun 8, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) technology. Bavituximab, a chimeric mAb against phosphatidylserine...
...12.6 months, HR=0.46, p=0.006). Oncologie Ltd., Cayman Islands Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen AG Phosphatidylserine Toll-like...
BioCentury | Jun 7, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) technology. Bavituximab, a chimeric mAb against phosphatidylserine...
...inhibitors (not reached vs. 12.6 months, HR=0.46, p=0.006). Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen AG Phosphatidylserine Toll-like...
BioCentury | Feb 16, 2018
Company News

Oncologie purchases bavituximab from Avid

...Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly...
...royalties. Oncologie is responsible for future research, development and commercialization of the chimeric mAb against phosphatidylserine...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...patients but not in placebo controls. 1771 / 1 Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Tarvacin bavituximab Phosphatidylserine...
BioCentury | Oct 17, 2016
Clinical News

Bavituximab: Interim Phase III data

...Calif. Product: Bavituximab ( 3G4 ) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine...
BioCentury | Mar 7, 2016
Clinical News

Bavituximab: Phase III discontinued

...Calif. Product: Bavituximab ( 3G4 ) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine...
BioCentury | Nov 16, 2015
Company News

Peregrine, AstraZeneca deal

...conduct both trials, which are expected to start next year. Bavituximab, a chimeric mAb against phosphatidylserine...
BioCentury | Nov 5, 2015
Distillery Techniques

Techniques: Platelet-specific anoctamin 6 (ANO6; TMEM16F)-knockout mouse model of Scott syndrome

...syndrome, a mild bleeding disorder. In Scott syndrome patients, platelets have low surface levels of phosphatidylserine...
...normal prothrombin formation and blood coagulation. Mice with systemic ANO6 knockout had lower levels of phosphatidylserine...
...model of platelet aggregation induced by laser irradiation of testicular veins, platelet-specific ANO6 knockout decreased phosphatidylserine...
Items per page:
1 - 10 of 129